Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has appointed Dr Robert Carroll as Partner, Head of Investor Relations. Carroll will lead the firm’s fundraising and investor relations team and brings a dedicated focus to supporting and growing Sofinnova Partners’ investor base.
Carroll has a decade of experience working with institutional investors and raising capital for alternative assets. Prior to joining Sofinnova Partners, he helped establish and co-lead PwC’s Global Fundraising Advisory Platform. Previously, Carroll worked at Mercury Capital Advisors, a global private fundraising and investment advisory firm, where he supported the needs of institutional investors and successfully raised capital across the alternative asset spectrum.
Prior to his career in private placement, Carroll, who holds a PhD in Chemistry from University College London, worked as a principal scientist and project lead at Pfizer, developing pharmaceutical assets from discovery to pre-clinical and into clinical trials. He also held positions at GlaxoSmithKline and Eli Lilly.
“We are thrilled to have Rob on board, and to be able to bring his deep scientific and financial experience to the helm of our investor relations,” says Antoine Papiernik, Managing Partner and Chairman of the firm. “Rob’s hire reflects the firm’s broader expansion and thoughtful, strategic growth,” he adds.
Papiernik says the company has more than EUR2 billion under management and that EUR1 billion has been raised in the last four years, while its team has continued to grow steadily.
Carroll says: “Sofinnova Partners continues to be a pioneer across the life sciences value chain with the recent addition of several new fund strategies, from acceleration to later-stage, and dedicated vehicles for gene and cell therapies, as well as industrial biotechnology. My priority will be to communicate the value our strategies can bring to the portfolios of our investors.”
Carroll completed his post-doctoral research at Brock University in Canada, with a focus on the semi-synthesis of morphine and its analogues. This work was carried out in collaboration with Noramco (then a part of Johnson & Johnson) and is the subject of a number of patents.